Cepheid (CPHD +1%) continues its upward trajectory today, having gained over 17% since last Thursday. Credit Suisse says it remains a top SMID cap pick given its best-in-class diagnostic testing platform and strong secular growth trends. Shares are Outperform rated with a $45 price target
More Stocks News
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com